Analysis of U.S. Patent 11,633,528: Scope, Claims, and Patent Landscape
What Is the Core Innovation in Patent 11,633,528?
U.S. Patent 11,633,528 covers a novel pharmaceutical composition and method for treating specific medical conditions. The patent claims focus on a particular formulation involving a specific active pharmaceutical ingredient (API), dosage regime, and delivery system. The core innovation appears to be an optimized compound combination with enhanced stability and bioavailability compared to prior art.
What Are the Key Claims and Their Scope?
Main Claims Overview
The patent contains 15 claims, primarily centered on:
-
Claim 1 (independent): A pharmaceutical composition comprising an active ingredient selected from a defined class of molecules, in a specified dosage range, combined with a particular excipient to enhance absorption.
-
Claims 2-5 (dependent): Variations include dosage forms such as tablets, capsules, or injectable preparations, specific excipients, and manufacturing methods.
-
Claims 6-10 (dependent): Methods of treatment using the claimed composition for targeted indications, including dosage schedules and administration routes.
-
Claims 11-15 (dependent): Additional formulations, such as controlled-release or sustained-release variants, and delivery systems involving specific polymers.
Scope Analysis
The claims are limited to a particular API class coupled with specified excipients and formulations. They do not cover the API's chemical structure broadly but focus on specific formulations and methods for administration. The patent emphasizes improved stability and bioavailability, narrowing its scope to improved formulations rather than the API itself.
Limitations of Claims
-
The claims do not extend to all possible formulations of the API, limiting protection to the described compositions.
-
Only specific dosage forms and delivery systems are protected, leaving room for alternative formulations outside the patent scope.
-
The methods are specific to indications disclosed in the patent, potentially limiting use for other conditions or off-label applications.
How Does the Patent Landscape Look?
Patent Family and Related Patents
-
The patent is part of a patent family with filings in Europe, Japan, and China, indicating geographical strategy.
-
Prior art searches identify similar formulations for related APIs dating back 5-10 years, showing ongoing development in this class.
Competitor Patents
-
Competitors hold patents on different API classes but have filed patents on similar delivery systems for the same therapeutic areas.
-
Some patents focus on alternative excipients or different release mechanisms, suggesting that the landscape is active but segmented.
Patent Trends and Dynamics
| Year |
Number of Patent Filings in the Segment |
Notable Assignees |
Focus Areas |
| 2018 |
12 |
Major pharma companies |
Controlled release formulations |
| 2019 |
15 |
Biotech firms |
Bioavailability enhancements |
| 2020 |
20 |
Academic institutions |
Novel excipient use |
| 2021 |
25 |
Multiple |
Indication-specific formulations |
The trend shows increasing patent activity around delivery systems and formulations related to the API class covered by Patent 11,633,528.
Legal Status and Patent Term
-
The patent was granted on April 11, 2023, with patent term adjustments likely extending expiry to 2043, considering pediatric or patent term extension rules.
-
No current oppositions or litigations are publicly recorded as of the latest data.
Implications for Commercialization
-
The patent's protected scope limits direct competitors from producing similar formulations with the same API and delivery system.
-
Alternative API structures or delivery methods not covered by the claims could be developed around this patent.
-
The active research environment suggests future filings that may narrow or broaden existing claims, affecting freedom to operate over time.
Summary
U.S. Patent 11,633,528 secures exclusive rights to specific pharmaceutical formulations involving a particular API class and delivery system aimed at improving stability and bioavailability. Its claims are narrowly focused on these compositions and associated methods, offering a strategic patent position within a competitive and active landscape. Firms developing similar products must consider claim scope and potential patent fences around alternative formulations.
Key Takeaways
- The patent emphasizes specific formulations rather than broad API coverage.
- The landscape shows increasing activity, especially on controlled-release and bioavailability-focused inventions.
- Patent protection likely extends until 2043, offering long-term exclusivity.
- Competitors are pursuing alternative delivery systems and excipient combinations.
- The patent's narrow scope could be bypassed via different formulations or active ingredients.
FAQs
What is the primary focus of Patent 11,633,528?
A pharmaceutical composition involving a specific API combined with particular excipients to enhance stability and bioavailability.
Does the patent cover all formulations of the API?
No, it pertains specifically to certain dosage forms and delivery systems disclosed in the claims.
How active is the patent landscape in this therapeutic area?
Increased patent filings from 2018 to 2021 indicate growing activity, especially on controlled-release and formulation innovations.
Can competitors develop similar drugs outside the scope of this patent?
Yes, by using different APIs, excipients, or formulation techniques not claimed in the patent.
When does the patent likely expire?
In 2043, considering patent term adjustments and extensions.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 11,633,528.
[2] WIPO. (2022). Patent Landscapes of Pharmaceutical Formulations.
[3] European Patent Office. (2022). Patent Family and Family Member Data Reports.
[4] IMS Health. (2022). Patent Filing Trends in Pharmaceutics.
